Sensipar

Sensipar is a brand name of cinacalcet, approved by the FDA in the following formulation(s):

SENSIPAR (cinacalcet hydrochloride - tablet; oral)

• 
  Manufacturer: AMGEN
  
  Approval date: March 8, 2004
  
  Strength(s): EQ 30MG BASE, EQ 60MG BASE, EQ 90MG BASE ^[RLD]

Has a generic version of Sensipar been approved?

No. There is currently no therapeutically equivalent version of Sensipar available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Sensipar. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Calcium receptor-active molecules
  Patent 6,011,068
  Issued: January 4, 2000
  Inventor(s): Nemeth; Edward F. & Van Wagenen; Bradford C. & Balandrin; Manuel F. & DelMar; Eric G. & Moe; Scott T.
  Assignee(s): NPS Pharmaceuticals, Inc.
  The Brigham and Women's Hospital
  The present invention relates to the different roles inorganic ion receptors have in cellular and body processes. The present invention features: (1) molecules which can modulate one or more inorganic ion receptor activities, preferably the molecule can mimic or block an effect of an extracellular ion on a cell having an inorganic ion receptor, more preferably the extracellular ion is Ca.sup.2+ and the effect is on a cell having a calcium receptor; (2) inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (3) nucleic acids encoding inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (4) antibodies and fragments thereof, targeted to inorganic ion receptor proteins, preferably calcium receptor protein; and (5) uses of such molecules, proteins, nucleic acids and antibodies.
  
  Patent expiration dates:
  
  
  • March 8, 2018
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Calcium receptor-active molecules
  Patent 6,031,003
  Issued: February 29, 2000
  Inventor(s): Nemeth; Edward F. & Van Wagenen; Bradford C. & Balandrin; Manuel F. & DelMar; Eric G. & Moe; Scott T.
  Assignee(s): NPS Pharmaceuticals, Inc.
  The Brigham and Women's Hospital
  The present invention relates to the different roles inorganic ion receptors have in cellular and body processes. The present invention features: (1) molecules which can modulate one or more inorganic ion receptor activities, preferably the molecule can mimic or block an effect of an extracellular ion on a cell having an inorganic ion receptor, more preferably the extracellular ion is Ca.sup.2+ and the effect is on a cell having a calcium receptor; (2) inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (3) nucleic acids encoding inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (4) antibodies and fragments thereof, targeted to inorganic ion receptor proteins, preferably calcium receptor protein; and (5) uses of such molecules, proteins, nucleic acids and antibodies.
  
  Patent expiration dates:
  
  
  • December 14, 2016
    
    ✓ 
    Patent use: METHOD OF DECREASING OR REDUCING PARATHYROID HORMONE LEVEL; METHOD OF MODULATING PARATHYROID HORMONE SECRETION;METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF REDUCING SERUM IONIZED CALCIUM LEVEL
  
  
  
  • December 14, 2016
    
  
  



• 
  Calcium receptor-active compounds
  Patent 6,211,244
  Issued: April 3, 2001
  Inventor(s): Van Wagenen; Bradford C. & Moe; Scott T. & Balandrin; Manuel F. & DelMar; Eric G. & Nemeth; Edward F.
  Assignee(s): NPS Pharmaceuticals, Inc.
  The present invention features compounds able to modulate one or more activities of an inorganic ion receptor and methods for treating diseases or disorders by modulating inorganic ion receptor activity. Preferably, the compound can mimic or block the effect of extracellular Ca.sup.2+ on a calcium receptor.
  
  Patent expiration dates:
  
  
  • October 23, 2015
    
    ✓ 
    Patent use: METHOD OF DECREASING PARATHYROID HORMONE LEVEL;METHOD OF TREATING HYPERPARATHYROIDISM
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Calcium receptor-active molecules
  Patent 6,313,146
  Issued: November 6, 2001
  Inventor(s): Van Wagenen; Bradford C. & Balandrin; Manuel F. & DelMar; Eric G. & Nemeth; Edward F.
  Assignee(s): NPS Pharmaceuticals, Inc.
  The present invention relates to the different roles inorganic ion receptors have in cellular and body processes. The present invention features: (1) molecules which can modulate one or more inorganic ion receptor activities, preferably the molecule can mimic or block an effect of an extracellular ion on a cell having an inorganic ion receptor, more preferably the extracellular ion is Ca.sup.2+ and the effect is on a cell having a calcium receptor; (2) inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (3) nucleic acids encoding inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (4) antibodies and fragments thereof, targeted to inorganic ion receptor proteins, preferably calcium receptor protein; and (5) uses of such molecules, proteins, nucleic acids and antibodies.
  
  Patent expiration dates:
  
  
  • December 14, 2016
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Rapid dissolution formulation of a calcium receptor-active compound
  Patent 7,829,595
  Issued: November 9, 2010
  Inventor(s): Lawrence; Glen Gary & Alvarez; Francisco J. & Lin; Hung-Ren H. & Ju; Tzuchi R.
  Assignee(s): Amgen Inc.
  The present invention relates to a pharmaceutical composition comprising a therapeutically effective amount of a calcium receptor-active compound and at least one pharmaceutically acceptable excipient, wherein the composition has a controlled dissolution profile. The present invention further relates to a method of manufacturing the pharmaceutical composition, as well as a method of treating a disease using the pharmaceutical composition.
  
  Patent expiration dates:
  
  
  • September 22, 2026
    
    ✓ 
    Patent use: METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF TREATING HYPERCALCEMIA
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • March 8, 2011 - ORPHAN DRUG EXCLUSIVITY
  
  
  • February 25, 2014 - TREATMENT OF SEVERE HYPERCALCEMIA IN PATIENTS WITH PRIMARY HYPERPARATHYROIDISM WHO ARE UNABLE TO UNDERGO PARATHYROIDECTOMY
  
  
  • February 25, 2014 - INCLUSION OF DATA FROM AN ADDITIONAL 19 SUBJECTS WITH HYPERCALCEMIA FROM PARATHYROID CARCINOMA TO THE INFORMATION CURRENTLY PRESENTED IN THE LABEL
  
  
  • February 25, 2018 - ORPHAN DRUG EXCLUSIVITY
  
  

See also...

• Sensipar Consumer Information (Drugs.com)
• Sensipar Consumer Information (Wolters Kluwer)
• Sensipar Consumer Information (Cerner Multum)
• Sensipar Advanced Consumer Information (Micromedex)
• Sensipar AHFS DI Monographs (ASHP)
• Cinacalcet Consumer Information (Wolters Kluwer)
• Cinacalcet Consumer Information (Cerner Multum)
• Cinacalcet Advanced Consumer Information (Micromedex)
• Cinacalcet AHFS DI Monographs (ASHP)